Siarhei Kirko
Research Subjects
Siarhei Kirko has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Zakrzeska
Department of Nursing, University of Medical Science in Bialystok, Krakowska 9, 15-875 Bialystok, Poland
1 shared publication - Aliaksei Bakunovich
Division of Biochemical Pharmacology, Institute of Biochemistry of Biologically Active Compounds, National Academy of Sciences, BLK, 50, 230030 Grodno, Belarus
1 shared publication - Dominika Szkopek
Large Animal Models Laboratory, The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, 05-110 Jabłonna, Poland
1 shared publication - Dorota Żyżelewicz
Institute of Food Technology and Analysis, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, 4/10 Stefanowskiego St., 90-924 Lodz, Poland
1 shared publication - Grażyna Budryn
Institute of Food Technology and Analysis, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, 90-537 Lodz, Poland
1 shared publication - Ilya B. Zavodnik
Department of Biochemistry, Yanka Kupala State University of Grodno, Bulvar Leninskogo Komsomola, 5, 230009 Grodno, Belarus
1 shared publication
Latest Publications
- Open Access
- 1 August 2025
- Published by MDPI AG in Preprints.org
The Domestic Pig as a Translational Model of Hyperoxaluria: Application to the Study of Oxalate-Dependent Renal Dysfunction
The purpose of this pilot study was to develop and characterize an in vivo porcine model of oxalate-induced renal injury using intravenous infusion of sodium oxalate (NaOx). 2 experimental regimens were developed to replicate acute and chronic hyperoxaluria. In the acute model, 3 different doses of 1% NaOx were administered over 15 hours, resulting in a dose-dependent increase in plasma oxalate concentration (Cmax: 42.4-122.4 µM) and transient hyperoxaluria, with a return to baseline values 6-8 hours after stopping the infusion of NaOx solution. In the chronic model, repeated infusions of NaOx for 7-11 days led to persistent hyperoxalemia (up to 302.4 µM), decreased appetite and increasing renal failure. Histological analysis revealed dose-dependent calcium oxalate (CaOx) deposits in renal tissue (1.85%-9.55% of renal surface area), consistent with moderate to severe nephrocalcinosis. The model represents the key clinical features of both acute kidney injury and the progressive nephrocalcinosis observed in primary hyperoxaluria and oxalaturia. Due to the physiological similarity between pigs and humans, the proposed porcine model is valuable for studying the pathophysiology of oxalate excess and for testing the efficacy of new therapies to counteract its toxicity.
- 1 August 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Domestic Pig as a Translational Model of Hyperoxaluria: Application to the Study of Oxalate-Dependent Renal Dysfunction
The purpose of this pilot study was to develop and characterize an in vivo porcine model of oxalate-induced renal injury using intravenous infusion of sodium oxalate (NaOx). 2 experimental regimens were developed to replicate acute and chronic hyperoxaluria. In the acute model, 3 different doses of 1% NaOx were administered over 15 hours, resulting in a dose-dependent increase in plasma oxalate concentration (Cmax: 42.4-122.4 µM) and transient hyperoxaluria, with a return to baseline values 6-8 hours after stopping the infusion of NaOx solution. In the chronic model, repeated infusions of NaOx for 7-11 days led to persistent hyperoxalemia (up to 302.4 µM), decreased appetite and increasing renal failure. Histological analysis revealed dose-dependent calcium oxalate (CaOx) deposits in renal tissue (1.85%-9.55% of renal surface area), consistent with moderate to severe nephrocalcinosis. The model represents the key clinical features of both acute kidney injury and the progressive nephrocalcinosis observed in primary hyperoxaluria and oxalaturia. Due to the physiological similarity between pigs and humans, the proposed porcine model is valuable for studying the pathophysiology of oxalate excess and for testing the efficacy of new therapies to counteract its toxicity.
- Open Access
Chlorogenic Acid Protects against Advanced Alcoholic Steatohepatitis in Rats via Modulation of Redox Homeostasis, Inflammation, and Lipogenesis
The aim of this study was to evaluate the therapeutic effects of chlorogenic acid (CGA) in rats with advanced alcoholic steatohepatitis. The rats were fed on a high-fat diet and gavaged with ethanol (4 g/kg) for 8 weeks. The livers of ethanol-treated rats showed steatosis; necrosis and mononuclear infiltration; and significant upregulation of the mRNA expression of the prooxidant (Cyp2e1, iNos), lipogenic (Srebp1, Acc), proinflammatory (Tlr4, Nf-κb, TnfA, Il-1B, and Il-6), and profibrogenic (TgfB, Col1, VegfA) genes. Simultaneously, a downregulation of level of Sod and Nrf2 was observed, which was accompanied by increased serum transaminase, TnfA, and serum and liver triglycerides levels. CGA administration (40 and 80 mg/kg, 8 weeks) to ethanol-fed group reduced the liver expression levels of Cyp2e1 and iNos, whereas it markedly enhanced the expression of Sod, Nrf2, and Ho-1. CGA at both doses downregulated the expressions of lipogenic, proinflammatory, and profibrogenic genes, while the expression of Tlr4 was lowered only after the higher dose of CGA. The higher dose of CGA efficiently prevented the progression of alcohol-induced steatosis and reduced inflammation through regulation of the expression of genes encoding the proteins involved in the Tlr4/Nf-κB signaling pathway and fibrosis. The study revealed hepatoprotective and anti-inflammatory effects of CGA through the regulation of expression of genes encoding Cyp2e1/Nrf2 involved in oxidative stress modulation. These results demonstrate CGA as a therapeutic candidate for the prevention and treatment of alcoholic steatohepatitis.
Open AccessChlorogenic Acid Protects against Advanced Alcoholic Steatohepatitis in Rats via Modulation of Redox Homeostasis, Inflammation, and Lipogenesis
The aim of this study was to evaluate the therapeutic effects of chlorogenic acid (CGA) in rats with advanced alcoholic steatohepatitis. The rats were fed on a high-fat diet and gavaged with ethanol (4 g/kg) for 8 weeks. The livers of ethanol-treated rats showed steatosis; necrosis and mononuclear infiltration; and significant upregulation of the mRNA expression of the prooxidant (Cyp2e1, iNos), lipogenic (Srebp1, Acc), proinflammatory (Tlr4, Nf-κb, TnfA, Il-1B, and Il-6), and profibrogenic (TgfB, Col1, VegfA) genes. Simultaneously, a downregulation of level of Sod and Nrf2 was observed, which was accompanied by increased serum transaminase, TnfA, and serum and liver triglycerides levels. CGA administration (40 and 80 mg/kg, 8 weeks) to ethanol-fed group reduced the liver expression levels of Cyp2e1 and iNos, whereas it markedly enhanced the expression of Sod, Nrf2, and Ho-1. CGA at both doses downregulated the expressions of lipogenic, proinflammatory, and profibrogenic genes, while the expression of Tlr4 was lowered only after the higher dose of CGA. The higher dose of CGA efficiently prevented the progression of alcohol-induced steatosis and reduced inflammation through regulation of the expression of genes encoding the proteins involved in the Tlr4/Nf-κB signaling pathway and fibrosis. The study revealed hepatoprotective and anti-inflammatory effects of CGA through the regulation of expression of genes encoding Cyp2e1/Nrf2 involved in oxidative stress modulation. These results demonstrate CGA as a therapeutic candidate for the prevention and treatment of alcoholic steatohepatitis.